Senti Biosciences Holdings, Inc. (SNTI)
SNTI moved a median of -0.19% 30 minutes after news, and -0.95% by the close. How SNTI actually reacts to news — the realized, point-in-time move the market made, measured across 319 labeled events over the last three years with zero look-ahead.
SNTI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 26% | 272 |
| 30-min | -0.19% | 40% | 301 |
| 60-min | -0.32% | 46% | 312 |
| to close | -0.95% | 37% | 317 |
| Middle 50% of SNTI reactions | -2.17% to +0.94% |
|---|---|
| Median reaction (30-min) | -0.19% |
| Measured reactions | 319 |
Half of all Senti Biosciences Holdings, Inc. news events land between -2.17% and +0.94% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SNTI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SNTI's baseline. Nothing else.
Recent SNTI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Techno | Press release | GlobeNewswire | -13.23% | -36.73% | |
| Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | Press release | GlobeNewswire | +2.80% | +8.00% | |
| Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase | Press release | GlobeNewswire | +2.80% | +8.00% | |
| Form 15-12G Senti Biosciences, Inc. | SEC filing · Form 15-12G | SEC EDGAR | +0.00% | +0.99% | |
| Form 8-K Senti Biosciences, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +3.69% | +2.35% | |
| Form EFFECT Senti Biosciences, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -4.03% | -6.58% | |
| Form 10-K/A Senti Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.03% | -6.58% | |
| Form 8-K12B Senti Biosciences, Inc. For: Apr 24 | SEC filing · Form 8-K12B | SEC EDGAR | -6.53% | -0.94% | |
| Form POS AM Senti Biosciences, Inc. | SEC filing · Form POS | SEC EDGAR | -2.33% | +1.87% | |
| Form S-8 Senti Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | -6.53% | -0.94% | |
| Form S-8 POS Senti Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | -6.53% | -0.94% | |
| Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 | Press release | GlobeNewswire | -0.34% | +1.17% | |
| Form 8-K Senti Biosciences, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -1.21% | +3.17% | |
| Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies | Press release | GlobeNewswire | +0.00% | -0.13% | |
| Form 10-K Senti Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.19% | -8.28% | |
| Form 8-K Senti Biosciences, Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -2.19% | -8.28% | |
| Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | -2.19% | -8.28% | |
| Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference | Press release | GlobeNewswire | — | — | |
| Form 8-K Senti Biosciences, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | +3.99% | +4.54% | |
| Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference | Press release | GlobeNewswire | +0.29% | +4.48% | |
| Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -1.19% | +4.79% | |
| Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development | Press release | GlobeNewswire | +0.00% | -4.44% | |
| Rett Syndrome Research Trust Announces 2025 Research Awards to Advance Genetic Medicines | Press release | PR Web | +0.00% | -4.44% | |
| Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) | Press release | GlobeNewswire | -1.33% | -5.88% | |
| Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 | Press release | GlobeNewswire | +1.00% | -2.00% | |
| Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation | Press release | GlobeNewswire | +0.00% | +3.77% | |
| Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference | Press release | GlobeNewswire | +0.00% | -0.89% | |
| Senti Biosciences Announces New Employment Inducement Grants | Press release | GlobeNewswire | -0.50% | +0.84% | |
| Form 8-K Senti Biosciences, Inc. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | -45.97% | |
| Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile | Press release | GlobeNewswire | -3.85% | -45.97% | |
| Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia | Press release | GlobeNewswire | -3.85% | -45.97% | |
| Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET | Press release | GlobeNewswire | +0.00% | -0.45% | |
| Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 | Press release | GlobeNewswire | +0.00% | -1.48% | |
| Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference | Press release | GlobeNewswire | +3.01% | -5.63% | |
| Senti Bio to Present at BioJapan | Press release | GlobeNewswire | +0.00% | +4.38% | |
| Senti Bio to Present at the MedInvest Biotech & Pharma Conference | Press release | GlobeNewswire | -1.45% | +0.72% | |
| Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | -0.68% | -3.38% | |
| Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech | Press release | GlobeNewswire | -1.96% | +0.00% | |
| Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia | Press release | GlobeNewswire | +0.50% | — | |
| Form 10-Q Senti Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.82% | -6.67% | |
| Form 8-K Senti Biosciences, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -1.82% | -6.67% | |
| Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 | Press release | GlobeNewswire | -1.82% | -6.67% | |
| Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia | Press release | GlobeNewswire | -2.33% | +0.00% | |
| Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference | Press release | GlobeNewswire | +1.98% | -1.49% | |
| Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum | Press release | GlobeNewswire | +0.00% | -1.00% | |
| Form 8-K Senti Biosciences, Inc. For: Jul 18 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -6.25% | |
| Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors | Press release | GlobeNewswire | -1.44% | -6.25% | |
| Form 8-K Senti Biosciences, Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | +2.34% | |
| Senti Bio Participates in Nasdaq Amplify Spotlight Series | Press release | GlobeNewswire | +0.00% | -1.40% | |
| Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference | Press release | GlobeNewswire | +2.04% | +2.04% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SNTI section they belong to.
Where else SNTI is measured.
SNTI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Senti Biosciences Holdings, Inc.'s median reaction calculated?
Every labeled SNTI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 319 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of SNTI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SNTI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.